Machine Learning Analysis of Post-Operative Tumour Progression in Non-Functioning Pituitary Neuroendocrine Tumours: A Pilot Study.
Ziad HusseinRobert W SlackStephanie E BaldewegEvangelos B MazomenosHani J MarcusPublished in: Cancers (2024)
Post-operative tumour progression in patients with non-functioning pituitary neuroendocrine tumours is variable. The aim of this study was to use machine learning (ML) models to improve the prediction of post-operative outcomes in patients with NF PitNET. We studied data from 383 patients who underwent surgery with or without radiotherapy, with a follow-up period between 6 months and 15 years. ML models, including k-nearest neighbour (KNN), support vector machine (SVM), and decision tree, showed superior performance in predicting tumour progression when compared with parametric statistical modelling using logistic regression, with SVM achieving the highest performance. The strongest predictor of tumour progression was the extent of surgical resection, with patient age, tumour volume, and the use of radiotherapy also showing influence. No features showed an association with tumour recurrence following a complete resection. In conclusion, this study demonstrates the potential of ML models in predicting post-operative outcomes for patients with NF PitNET. Future work should look to include additional, more granular, multicentre data, including incorporating imaging and operative video data.
Keyphrases
- machine learning
- big data
- electronic health record
- signaling pathway
- end stage renal disease
- early stage
- oxidative stress
- radiation therapy
- ejection fraction
- chronic kidney disease
- high resolution
- minimally invasive
- type diabetes
- newly diagnosed
- randomized controlled trial
- clinical trial
- deep learning
- mass spectrometry
- lps induced
- radiation induced
- metabolic syndrome
- locally advanced
- adipose tissue
- climate change
- cross sectional
- peritoneal dialysis
- photodynamic therapy
- study protocol
- inflammatory response
- decision making
- current status
- rectal cancer
- immune response